Discussion about this post

User's avatar
Keith R. Holden, M.D.'s avatar

"The genetic fingerprint, not the anatomical location, determines which treatments will work." That statement is true to a certain degree. The human body, under siege by cancer, is more than just a genetic blueprint that responds to pharmaceutical manipulation. It is a complex web of interactive organ systems, each of which contributes to the success or failure of an anti-cancer regimen. Research indicates that if the microbiome exhibits specific imbalances, checkpoint inhibitors for cancer may be less effective or ineffective. Suppose CureWise is to be most effective for all who enter data. In that case, it must take into account the imbalances that exist in each organ system and consider effective therapies for those systems, if the anti-cancer regimen recommended is to work for everyone. Toxin overload (exogenous or endogenous), micronutrient deficiency, systemic inflammation, and uncontrolled stress responses are just a few examples. Best of luck with the ingenious program!

Expand full comment

No posts